The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Akero Therapeutics has a market capitalization of US$1.2b, so we would expect some institutional investors to have noticed the stock. NASDAQ data is at least 15 minutes delayed.
To learn more, You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Log in to see them here or sign up to get started.Create a list of the investments you want to track.Visit a quote page and your recently viewed tickers will be displayed here.French biotech Genfit, which had been expected to bring one of the first drugs to market to treat nonalcoholic steatohepatitis, said it is getting out of the race altogether.In a report released today, Michael Morabito from Chardan Capital initiated coverage with a Buy rating on Akero Therapeutics (AKRO) and a price ...[...]Corcept's Phase 3 Trial, And Other News: The Good, Bad And Ugly Of BiopharmaAkero Therapeutics (AKRO) Reports Biopsy Data and Safety/Tolerability for 16-Week Phase 2a Study in NASH Patients - SlideshowAkero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.Akero reports additional positive data on lead candidate in NASH patientsAkero to release new data on lead candidate in NASH after the closeAkero Therapeutics to announce new data from AKR-001 Phase 2a NASH studyThere’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akero Therapeutics (AKRO), Cara Therapeutics ...[...]Dosing underway in Akero's expanded cohort of Balanced trial in NASHAkero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. All information is required.As an alternative to using this form, you can send us your name and zacks account email with your request to privacy@zacks.com.We'll send a verification email to the email address you provided. The monthly returns are then compounded to arrive at the annual return. Large market cap companies give stability and are good long-term investments. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. It is calculation of the company's share price times the number of outstanding shares. We use cookies to understand how you use our site and to improve your experience. We're driving the transformation of our market. Here’s where things stand on the extra $600 a week in unemployment benefits that expired Friday, and why are ‘Karens’ so angry? Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Learn More About Our Products & Services See how our digital-first products and services can benefit your business. This information will only be used for this request. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.33% per year.
]Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.Is (AKRO) Outperforming Other Medical Stocks This Year?Copyright © 2020 MarketWatch, Inc. All rights reserved.
By using this site you agree to the There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.As an investor, you want to buy stocks with the highest probability of success.